<DOC>
	<DOCNO>NCT00070018</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Monoclonal antibody , rituximab yttrium Y 90 ibritumomab tiuxetan , locate cancer cell either kill deliver radioactive cancer-killing substance without harm normal cell . Combining chemotherapy radiation therapy monoclonal antibody therapy may kill cancer cell . PURPOSE : This phase II trial study well give combination chemotherapy together radiation therapy monoclonal antibody therapy work treat patient stage I stage II non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>S0313 Cyclophosphamide , Doxorubicin , Vincristine , Prednisone , Radiation Therapy Followed By Rituximab Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Stage I Stage II Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine 2-year progression-free survival patient aggressive high-risk stage I IE non-bulky stage II IIE CD20-positive non-Hodgkin 's lymphoma treat cyclophosphamide , doxorubicin , vincristine , prednisone radiotherapy follow rituximab yttrium Y 90 ibritumomab tiuxetan . - Determine toxicity regimen patient . OUTLINE : This multicenter study . - Chemotherapy : Patients receive CHOP chemotherapy comprise cyclophosphamide IV 1-2 hour , doxorubicin IV , vincristine IV day 1 oral prednisone day 1-5 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . - Radiotherapy : Beginning 3 week completion CHOP chemotherapy , patient undergo radiotherapy daily 5 day week 4-5 week . - Monoclonal antibody therapy : Beginning 3-6 week completion radiotherapy , patient receive rituximab IV follow indium In 111 ibritumomab tiuxetan IV 10 minute day 1 . Patients undergo whole body image . If ibritumomab tiuxetan biodistribution acceptable , patient receive rituximab IV yttrium Y 90 ibritumomab tiuxetan IV 10 minute day 7 , 8 , OR 9 . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive nonHodgkin 's lymphoma 1 follow subtypes : Diffuse large Bcell Mantle cell Highgrade Bcell , Burkitt 's , Burkittlike Anaplastic large cell ( Bcell phenotype ) Stage I , IE , nonbulky* stage II IIE disease Ann Arbor classification Patients bulky stage II IIE disease ineligible even , resection , measurement le 10.0 cm NOTE : *Nonbulky disease define tumor measure less 10.0 cm occupy less 1/3 chest diameter CD20expressing disease flow cytometry immunoperoxidase stain Aggressive lymphoma must least 1 follow adverse prognostic factor : Nonbulky stage II IIE disease At least 60 year age Zubrod performance status 2 Lactic dehydrogenase great upper limit normal All disease must encompassable single radiation port ( include site resect disease ) NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age Over 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No medical contraindication study chemotherapy , rituximab , ibritumomab tiuxetan No known AIDS syndrome HIVassociated complex PRIOR CONCURRENT THERAPY : Biologic therapy No prior monoclonal antibody therapy Chemotherapy No prior chemotherapy lymphoma Endocrine therapy Not specify Radiotherapy See Disease Characteristics No prior radiotherapy lymphoma No concurrent intensitymodulated radiotherapy Planned involvedfield radiotherapy must encompass 25 % active bone marrow space Surgery See Disease Characteristics Other Concurrent participation SWOG8947 SWOG8819 allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
</DOC>